Early-stage classical Hodgkin lymphoma (stage I to II): lines of therapy

Cancer page →

5 standard-of-care settings across 4 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers	Age group
Screening, prevention and diagnosis	1	·
Early / localised	2	·
Special situations	1	·
Other settings	·	1

Screening, prevention and diagnosis

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Staging	FDG-PET/CT with Lugano staging; bone marrow biopsy no longer needed when PET is used; fertility counselling and cardiac baseline.	FDG PETLugano classification / Ann Arbor stagingOncofertility and fertility preservationCardio-oncology	NCCN Guidelines: Hodgkin Lymphoma	79

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Early favourable disease	Two cycles of ABVD with 20 Gy involved-site radiotherapy (HD10); or PET-adapted chemotherapy alone (three ABVD if PET-negative after two, RAPID and H10) accepting a small increase in relapse.	DoxorubicinVinblastineDacarbazineABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)IMRT / IGRT (modern external beam)PET-adapted (response-adapted) therapyDeauville five-point scale	NCCN Guidelines: Hodgkin Lymphoma	93
All comers	Early unfavourable disease	Four cycles of ABVD (or two escalated BEACOPP plus two ABVD) with 30 Gy involved-site radiotherapy; radiotherapy omitted in PET-negative patients after HD17.	DoxorubicinVinblastineDacarbazineABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)IMRT / IGRT (modern external beam)PET-adapted (response-adapted) therapy	NCCN Guidelines: Hodgkin Lymphoma	93

Special situations

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Survivorship	Cardiac surveillance, breast screening from eight years after chest radiotherapy in women, thyroid checks and second-cancer awareness for life.	Cardio-oncologyMammography & tomosynthesisLate effects and survivorship toxicity	NCCN Guidelines: Hodgkin Lymphoma	89

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
Age group	Children and adolescents	Response-adapted Children's Oncology Group regimens with radiotherapy for slow responders; AHOD2131 tests brentuximab vedotin with nivolumab.	AHOD2131 (COG / NCTN)Brentuximab vedotinNivolumabChildren's Oncology Group (COG)	NCCN Guidelines: Hodgkin Lymphoma	86

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.